United Therapeutics | UTHR - Equity Capital And Reserves


United Therapeutics reported $5.9B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Amarin USD 449.41M 9.87M Mar/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026